Visit https://www.peervoice.com/HWT860 to view the entire programme with slides. After completing “Quality of Life in Patients With Advanced Renal Cell Carcinoma: Are We Measuring What Matters?”, participants will be able to: Describe the impact of advanced renal cell carcinoma (aRCC) on patients’ quality of life (QoL) and its assessment with evidence-based tools; Summarise the latest QoL data for therapeutic strategies for untreated aRCC; Appraise how the QoL data alongside the efficacy/safety data may inform the individualised management of patients with aRCC now and into the future